Caplin Point Laboratories Limited
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.
What Caplin files
- Others44
- Investor Meet25
- Important14
- Updates14
- Board Meeting7
- Dividend/Bonus5
Caplin Point's subsidiary, Caplin Steriles, secured USFDA approval for Foscarnet Sodium Injection. This generic targets a US market with annual sales of ~$15 million, enhancing future revenue opportunities.
Caplin Point's subsidiary, Caplin Steriles, received USFDA approval for Calcium Gluconate Injection. This opens access to a US market with $71 million in annual sales, signifying a new revenue opportunity.
Caplin Steriles (subsidiary) secured USFDA final approval for Potassium Phosphates Injection. This generic targets a US market with annual sales of $57 million (~₹5.7 Cr), significantly expanding Caplin Point's product portfolio and market reach.
Caplin Point's subsidiary, Caplin Steriles, secured approval for Desmopressin Acetate Injection. This generic drug targets a US market with annual sales of approx. 215.8 Cr ($26 million), enhancing future revenue potential.
Caplin Point's subsidiary, Caplin Steriles, gained USFDA approval for Sodium Phosphates Injection. This generic drug competes in a US market with annual sales of approximately US$67 million, strengthening its regulated market footprint.